Ken Griffin Iveric Bio, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$26.24 - $39.63 $7.29 Million - $11 Million	277,924 Added 1270.68%	299,796 $11.8 Million
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $3.93 Million - $5.16 Million	-210,297 Reduced 90.58%	21,872 $532,000
Q4 2022 Feb 14, 2023	SELL	$17.24 - $23.95 $40.1 Million - $55.7 Million	-2,326,202 Reduced 90.93%	232,169 $4.97 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $22.4 Million - $44.4 Million	2,388,227 Added 1403.65%	2,558,371 $45.9 Million
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $989,255 - $2.05 Million	108,471 Added 175.88%	170,144 $1.64 Million
Q1 2022 May 16, 2022	BUY	$12.15 - $16.83 $371,146 - $514,106	30,547 Added 98.14%	61,673 $1.04 Million
Q4 2021 Feb 14, 2022	SELL	$13.83 - $18.78 $9.08 Million - $12.3 Million	-656,654 Reduced 95.47%	31,126 $520,000
Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $2.06 Million - $5.1 Million	291,636 Added 73.62%	687,780 $11.2 Million
Q2 2021 Aug 16, 2021	SELL	$5.69 - $7.17 $2.85 Million - $3.59 Million	-500,791 Reduced 55.83%	396,144 $2.5 Million
Q1 2021 May 17, 2021	SELL	$5.08 - $6.89 $8.84 Million - $12 Million	-1,739,384 Reduced 65.98%	896,935 $5.54 Million
Q4 2020 Feb 16, 2021	BUY	$5.65 - $7.66 $8.11 Million - $11 Million	1,434,972 Added 119.45%	2,636,319 $18.2 Million
Q3 2020 Nov 16, 2020	BUY	$4.01 - $6.29 $4.6 Million - $7.22 Million	1,147,964 Added 2150.43%	1,201,347 $6.78 Million
Q2 2020 Aug 14, 2020	BUY	$3.06 - $6.6 $78,446 - $169,197	25,636 Added 92.39%	53,383 $272,000
Q4 2019 Feb 14, 2020	BUY	$0.93 - $8.58 $25,804 - $238,069	27,747 New	27,747 $238,000

Others Institutions Holding ISEE

# of Institutions

Shares Held

250K

Call Options Held

40K

Put Options Held

View Full List

About IVERIC bio, Inc.

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

More about ISEE

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account